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Deciphering the coagulation profile 
through the dynamics of thrombin 
activity
Romy M. W. de Laat‑Kremers1,2*, Qiuting Yan1,2, Marisa Ninivaggi1, Moniek de Maat3 & 
Bas de Laat1,2
Thrombosis has proven to be extremely difficult to predict. Measuring the generation of thrombin is 
a very sensitive method to detect changes in the hemostatic system. We developed a method based 
on the generation of thrombin to further fingerprint hemostasis, which we have named thrombin 
dynamics. Via this method we are able to exactly measure the prothrombin conversion and thrombin 
inactivation, and any change in the coagulation cascade will be reflected in these two processes. 
In the current study we analyzed the importance of the members of the prothrombin complex on 
the dynamics of thrombin activation and inactivation. We show that prothrombin conversion is 
predominantly influenced by factor X and antithrombin, which will provide essential insights in 
complex thrombosis-related diseases, such as liver cirrhosis and kidney failure.
Thrombin is the key enzyme in the coagulation cascade and converts fibrinogen into a fibrin network. The 
thrombin generation (TG) test measures the amount of thrombin that is generated in plasma in response to a 
tissue factor  stimulus1. TG is a widely used method to screen for hyper- and hypo-coagulability2, as increased 
TG is associated with thrombosis, and vice versa, reduced TG is related to  bleeding2–8. Additionally it is often 
used to assess therapeutic strategies, both in  research9,10 and in the  clinic11,12. It is a global coagulation assay 
and subsequently, a deviant TG profile cannot be immediately attributed to a specific coagulation  defect1,2 and 
further testing is required.
The thrombin generation describes the amount present in clotting plasma at each time point during the meas-
urement. The thrombin concentration depends on two main underlying processes: the production of thrombin 
(prothrombin conversion) and inactivation of  thrombin13. A reduction of TG can be caused by lower activation of 
the prothrombin conversion or increased thrombin inhibition. Recently, we developed a method called thrombin 
dynamics analysis to study the processes that underlie thrombin generation in more  detail14. In this method, 
we quantify prothrombin conversion and thrombin inactivation from TG data, allowing these processes to be 
studied independently from each other. The rate of thrombin inactivation is predicted with an algorithm based 
on the plasma antithrombin (AT), α2Macroglobulin (α2M) and fibrinogen  level14. Subsequently, the prothrombin 
conversion curve can be extracted from the thrombin generation curve. From this prothrombin conversion curve, 
the peak value and the area-under-the-curve are quantified (Fig. 1), respectively representing the maximum 
rate of the prothrombinase complex  (PCmax) and the total amount of prothrombin converted throughout the 
measurement  (PCtot). The amount of thrombin-antithrombin (T-AT) and thrombin-α2Macroglobulin (T-α2M) 
complexes formed during the experiment are quantified. The thrombin inactivation capacity (TDC) is calculated 
independent from the TG curve and depends solely on the AT, α2M and fibrinogen level of a plasma sample.
The dynamics of thrombin generation have been studied in multiple clinical settings over the past years to 
study the balance between pro-and anticoagulant mechanisms, and to perform in silico experimentation to 
generate  hypotheses14–22. Recently, questions have started to emerge about the influence of individual coagula-
tion factor levels on the parameters of prothrombin conversion and thrombin inactivation. It is of interest to 
study the contribution of specific coagulation factors to the individual parameters in order to further fingerprint 
coagulation. This allows the better interpretation of in silico results and the generation of new working hypotheses 
based on the in silico work. Another important question that needs to be addressed is when the novel parameters 
should be considered abnormal. Until now, reference ranges were not available for prothrombin conversion and 
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thrombin inactivation parameters, which makes it difficult to interpret the assays results clinically when a study 
is performed in a clinical setting. Especially in the case of in silico experimentation on clinical data, reference 
values are an important tool to define what is considered normal and what is not.
Thrombin is the last enzyme of the coagulation cascade which converts fibrinogen into fibrin thereby chang-
ing the liquid blood into a solid compound. Any change in the coagulation factors will have an effect on the 
generation and activity of thrombin. In the current study, we investigated the effect of individual coagulation 
factors mostly belonging to the prothrombinase complex on the dynamics of thrombin activity using thrombin 
generation, prothrombin conversion and thrombin inactivation as read out.
Results
Even though the thrombin dynamics method has shown its added value to thrombin generation data in several 
clinical studies in the past years, the meaning of each parameter in the wider context of coagulation has yet to be 
 investigated14–22. In this study, we investigated the effect of four major coagulation factors (prothrombin, FV, FX, 
and antithrombin) on five thrombin dynamics parameters  (PCtot,  PCmax, T-AT, T-α2M, and TDC). We chose to 
study prothrombin, FV and FX because they are components of the prothrombinase complex, converting pro-
thrombin into active thrombin. In addition, antithrombin was studied because it is the most important natural 
thrombin inhibitor. The role of each individual coagulation factor was investigated by performing dose–response 
Figure 1.  Illustration of the quantification of thrombin dynamics parameters. (A) The total amount of 
prothrombin converted  (PCtot) is quantified as the area under the curve of the prothrombin conversion curve. 
(B) The maximum rate of prothrombin conversion  (PCmax) is defined as the peak of the prothrombin conversion 
curve. (C, D) The total amount of prothrombin converted during TG equals the total amount of thrombin-
inhibitor complexes formed (gray area). This is split into thrombin-antithrombin complex formation (T-AT; C) 
and thrombin-α2Macroglobulin formation (T-α2M; D).
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measurements in plasma deficient in that specific factor and by performing correlation analysis in a group of 
healthy subjects (n = 122).
The effect of plasma prothrombin level on the dynamics of thrombin generation. We first 
investigated the effect of prothrombin on thrombin generation, prothrombin conversion and thrombin inactiva-
tion. The plasma prothrombin level has a strong dose-dependent effect on thrombin generation (Supplementary 
Fig. 1).
Below the threshold of 20%, prothrombin shortens the lag time and time-to-peak dose-dependently, and 
the prothrombin level correlates almost perfectly with ETP and peak at 5 pM TF  (R2 = 0.972 and  R2 = 0.971, 
respectively). We used thrombin dynamics analysis to further fingerprint the effect of the prothrombin level on 
thrombin generation. As expected, we found that prothrombin dose-dependently increases prothrombin conver-
sion (Fig. 2A–F). Not only  PCtot, but also T-AT and T-α2M are linearly correlated with the plasma prothrombin 
level (all  R2 > 0.973) and  PCmax increases with increasing prothrombin levels, which is most pronounced at high 
TF concentrations.
In healthy subjects, both  PCtot and T-AT are correlated to the plasma prothrombin level at 1 pM TF  (R2 = 0.136 
and  R2 = 0.131, respectively with p < 0.0001) and at 5 pM TF  (R2 = 0.183 and  R2 = 0.195, respectively with 
p < 0.0001). TDC does not depend on prothrombin in in vitro dose–response experiments (Supplementary 
Fig. 2), nor in healthy subjects.
Figure 2.  The effect of prothrombin and antithrombin on the dynamics of thrombin generation. (A–F) 
Prothrombin deficient plasma was mixed with pooled normal to achieve plasma concentrations of 0, 5, 10, 
20, 30, 40, 50, 60, 70, 80, 90, and 100% prothrombin. Prothrombin conversion curves at 1 (A) and 5 pM TF 
(B) are shown (0–100% prothrombin from bottom to top) and thrombin dynamics parameters  PCtot (C), the 
 PCmax (D), T-AT complexes (E) and T-α2M complexes (F) were quantified at 1 pM TF (■ symbols) and 5 pM 
TF (● symbols). (G–L) Antithrombin deficient plasma was mixed with pooled normal to achieve plasma 
concentrations of 40, 50, 60, 70, 80, 90, and 100% antithrombin. Prothrombin conversion curves at 1 (G) and 
5 pM TF (H) are shown (0–100% antithrombin from top to bottom and thrombin dynamics parameters  PCtot 
(I), the  PCmax (J), T-AT complexes (K) and T-α2M complexes (L) were quantified at 1 pM TF (■ symbols) and 
5 pM TF (● symbols). The average results of 3 experiments are shown as the mean ± SD.
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The effect of plasma AT level on the dynamics of thrombin generation. Secondly, we quanti-
fied the effect of the natural anticoagulant antithrombin on thrombin generation, prothrombin conversion and 
thrombin inactivation. Thrombin generation was measured above an antithrombin level of 40% (Supplementary 
Fig. 1) and thrombin dynamics parameters were quantified (Fig. 2G–L). Due to experimental limitations, throm-
bin generation cannot be measured in plasma samples containing less antithrombin because then prothrombin 
levels exceed antithrombin levels, causing ongoing thrombin generation and subsequent substrate depletion. 
Antithrombin significantly prolongs the thrombin generation lag time and time-to-peak is inversely correlated 
with the ETP and peak (p < 0.001). We used thrombin dynamics analysis to investigate whether antithrombin 
only influences the inactivation of thrombin, or prothrombin conversion as well. Predominantly the maximum 
rate of prothrombin conversion  (PCmax) was attenuated by antithrombin (Fig. 2G-L). We also found that the 
amount of thrombin-α2M complexes formed during thrombin generation was reduced at increasing antithrom-
bin concentrations (p < 0.001). In healthy subjects, we were able to confirm that the AT level was significantly 
correlated to the T-α2M level at 1 pM TF  (R2 = 0.132 with p < 0.0001) and 5 pM TF  (R2 = 0.158 with p < 0.0001). In 
addition, the thrombin decay constant strongly depends on the plasma AT level in the dose–response measure-
ments (Supplementary Fig. 2) and in healthy subjects  (R2 = 0.537, p < 0.0001).
The effect of plasma FV level on the dynamics of thrombin generation. Factor V is one of the 
prominent members of the prothrombinase complex and we tested its role in thrombin generation, prothrombin 
conversion and thrombin inactivation. FV dose-dependently shortened the lag time and time-to-peak, espe-
cially below 20% FV (Supplementary Fig. 3).
Additionally, FV increased the TG peak height and ETP dose-dependently (p = 0.004 and p < 0.001). Using 
thrombin dynamics analysis, we found that the FV increases thrombin generation at low TF levels by stimulating 
the production of thrombin  (PCtot, p = 0.0023), which subsequently increases the formation of T-AT and T-a2M 
(p = 0.048 and p = 0.0045, respectively; Fig. 3A-F).
At 5 pM TF, FV did not significantly affect any of the thrombin dynamics parameters. In contrast, in healthy 
subjects FV did not show a significant correlation with any of the thrombin dynamics parameters. Furthermore, 
the thrombin decay constant did not depend on the plasma FV level (Supplementary Fig. 2), and also in the 122 
healthy subjects, FV did not correlate with the thrombin decay constant.
The effect of plasma FX level on the dynamics of thrombin generation. Factor X levels were 
measured and studied for their influence on thrombin. FX dose-dependently increased the thrombin generation 
peak height and ETP (p < 0.001 and p = 0.0004) and shortens the lag time and TTP. Thrombin dynamics analysis 
revealed that TG increases because of an increase of  PCtot, T-AT and T-α2M in the lower range of FX (Fig. 3G–L), 
whereas the thrombin decay constant was not affect by the plasma FX level (Supplementary Fig. 2). Factor X 
levels above 40% did not increase  PCtot, T-AT and T-α2M any further and resulted in a plateau (all p < 0.0001). 
Additionally,  PCmax increased dose-dependently with the FX level (p < 0.0001), most pronouncedly at 5 pM TF. 
In healthy subjects, the plasma FX level correlates significantly with  PCtot at 1 and 5 pM TF  (R2 = 0.101 and 
 R2 = 0.142 with p < 0.0005) and T-AT at both 1 and 5 pM TF  (R2 = 0.102 and  R2 = 0.151 at p < 0.0001), but not 
T-α2M.
Reference values for thrombin dynamics. In order to define normal values for thrombin dynamics 
parameters, we measured thrombin generation and thrombin dynamics in 122 healthy subjects at 1 and 5 pM 
TF (Supplementary Table 1). We defined the reference ranges as the 2.5th and 97.5th percentile for the thrombin 
dynamics parameters in the whole group of healthy subjects (n = 122), which are depicted in Fig. 4 as grey boxes. 
The total amount of prothrombin converted  (PCtot) ranged from 693 to 1,344 and from 746 to 1,335 for TG trig-
gered with 1 and 5 pM TF, respectively. The maximum prothrombin conversion rate  (PCmax) ranged from 109 to 
415 for 1 pM TF, and from 153 to 474 for 5 pM TF. Thrombin-antithrombin complexes ranged from 667 to 1,283 
for 1 pM TF and from 729 to 1,279 for 5 pM and thrombin-α2-macroglobulin ranged from 16 to 63 both for 1 
and 5 pM TF. The thrombin decay capacity ranged from 0.633 to 1.002 min-1 with a median value of 0.816 min-1.
The dynamics of thrombin generation in men vs. women and the effect of oral contracep‑
tives. As oral contraceptives have been shown to affect coagulation and the generation of thrombin via an 
effect on the protein C pathway we studied possible differences between men, women with/without OC in more 
detail. Figure 4 shows the average thrombin generation and prothrombin conversion curves for the subset of 
men (n = 60), women without oral contraceptives (OC; n = 47), and women with OC (n = 15). As expected from 
previous studies, thrombin generation was significantly higher in women than in men (ETP + 8%, p = 0.043) 
when measured at 1 pM TF. Within the group of women, the ETP was significantly higher in women using OC 
(+ 25%, p < 0.01) compared to women without OC. No difference was found between men and women without 
OC. To understand these differences in TG, we studied thrombin dynamics parameters in men, women with-
out OC, and women with OC. We found that  PCtot (+ 14.4% and + 9.5% for 1 and 5 pM TF),  PCmax (36.9 + % 
and + 46.1% for 1 and 5 pM TF), and T-AT (+ 14.3% and + 9.5% for 1 and 5 pM TF) were significantly elevated in 
women with OC compared to women without OC. T-α2M formation was unaffected by OC use. No differences 
were found between men and women without OC.
the main determinants of thrombin dynamics parameters. We investigated in more detail pos-
sible combined effects of our input coagulation factors. Therefore, 3D plots were drawn in order to depict the 
relationship between each thrombin dynamics parameters and its two most important influencing coagulation 
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factors. We found that  PCtot is mainly dependent on prothrombin and FX levels, and low levels of either coagula-
tion factor lead to lower prothrombin conversion (Fig. 5A).  PCmax is mainly dependent on prothrombin and FX 
(Fig. 5B). Thrombin-antithrombin formation is mostly dependent on the levels of prothrombin and FX as high 
prothrombin or FX levels are associated with high amounts of T-AT complexes formed (Fig. 5C). Figure 5D 
shows that thrombin-α2macroglobulin formation is high when as expected α2M levels are high, and T-α2M for-
mation is low when α2M is low. The thrombin decay capacity mainly depends on antithrombin and fibrinogen 
levels, and high TDC is associated with high antithrombin levels and low fibrinogen levels (Fig. 5E).
Prothrombin conversion and thrombin inactivation in haemophilia A. To illustrate the thrombin 
dynamics method further, we measured thrombin generation, prothrombin conversion and thrombin inactiva-
tion in 8 hemophilia A patients. Figure 6A,B show the average thrombin generation curve and prothrombin con-
version curve at 1 pM TF in hemophilia A patients and 60 healthy male controls. Both the rate of prothrombin 
conversion and the amount of prothrombin converted is reduced in hemophilia (Fig. 6C,D). Subsequently. T-AT 
and T-α2M complex formation was significantly lower in patients compared to controls (Fig. 6E,F).
Discussion
Thrombin is the central enzyme in coagulation by converting fibrinogen into fibrin thereby forming a clot. Any 
change in the coagulation cascade will be depicted in the generation and activity of thrombin. Thrombin gen-
eration is a sensitive method to investigate these changes but this method will not provide detailed reasons why 
Figure 3.  The effect of FV and FX on the dynamics of thrombin generation. (A–F) FV deficient plasma was 
mixed with pooled normal to achieve plasma concentrations of 0, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100% 
FV. Prothrombin conversion curves at 1 (A) and 5 pM TF (B) are shown (0–100% FV from bottom to top) 
and thrombin dynamics parameters  PCtot (C), the  PCmax (D), T-AT complexes (E) and T-α2M complexes (F) 
were quantified at 1 pM TF (■ symbols) and 5 pM TF (● symbols). (G–L) FX deficient plasma was mixed 
with pooled normal to achieve plasma concentrations of 0, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100% FX. 
Prothrombin conversion curves at 1 (G) and 5 pM TF (H) are shown (0–100% FX from bottom to top and 
thrombin dynamics parameters  PCtot (I), the  PCmax (J), T-AT complexes (K) and T-α2M complexes (L) were 
quantified at 1 pM TF (■ symbols) and 5 pM TF (● symbols). The average results of 3 experiments are shown 
as the mean ± SD.
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the coagulation behaves differently in certain situations. In the current study, we hypothesized that each specific 
coagulation factor has a ‘fingerprint’, a specific influence on thrombin dynamics, which is initially revealed as a 
deviation in the TG profile. Thrombin dynamics is a method that goes further into detail quantifying the pro-
thrombin conversion and the thrombin decay. By using thrombin dynamics we were able pinpoint how factor 
II, V, X, antithrombin and α2M affect the generation of thrombin.
Changes in thrombin generation are caused by specific changes in the underlying processes of prothrombin 
conversion and thrombin inactivation. Prothrombin conversion is not only influenced by procoagulant factors 
prothrombin and FX, but also by antithrombin. The total amount of prothrombin conversion is dependent on the 
available amount of prothrombin in the plasma, which is intuitively logical. In contrast, the maximum velocity 
of prothrombin conversion is not only dependent on the plasma level of prothrombin and FX, but also on the 
antithrombin level. This finding is in line with the data of Cvirn et al. that show that an increase of antithrombin 
levels reduces the amount of prothrombin fragment 1 + 2  formation23. Furthermore, according to the laws of 
enzyme kinetics, the prothrombin level is a rate limiting factor for the maximum prothrombin conversion veloc-
ity because it is the substrate for the prothrombinase  complex24. The other (theoretical) rate limiting factor is 
the concentration of the enzyme of the prothrombinase complex, FX, which is confirmed by our experimental 
results. Therefore, a lower prothrombin or FX, and especially the combination of lower levels of both, result in a 
reduced  PCmax. Indeed, in a previous study we found a reduction of  PCmax in patients on vitamin K  antagonists22.
The formation of thrombin-antithrombin and thrombin-α2macroglobulin complexes depends on the plasma 
level of the respective inhibitor and the prothrombin level. Low prothrombin levels and subsequently low 
Figure 4.  Reference values for thrombin dynamics parameters determined in 122 healthy subjects. Thrombin 
generation and thrombin dynamics were determined at 1 pM TF (A–F) and 5 pM TF (G–L). Average thrombin 
generation curves at 1 and 5 pM TF (A and G) were calculated for 3 groups: men (black), women without oral 
contraceptives (OC; red) and women with OC (blue). Average prothrombin conversion curve at 1 and 5 pM 
TF were calculated for the same groups (B,H). Reference ranges were determined for thrombin dynamics 
parameters at 1 and 5 pM TF:  PCtot (C,I),  PCmax (D,J), T-AT (E,K) and T-α2M (F,L). Reference ranges are 
depicted as grey boxes, dots show individual values and the lines indicate the median ± interquartile range. 
Statistical significance was tested by ANOVA with Bonferroni correction was indicated as *p < 0.05, **p < 0.001, 
and *** < p < 0.001.
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prothrombin conversion lead to low T-AT and T-αM formation, simply because thrombin needs to be available 
to be inhibited. Nevertheless, the antithrombin and α2Macroglobulin have a large effect on the amount of T-AT 
and T-α2M formed, respectively, and the ratio between the two types of enzyme-inhibitor complexes. In patients 
treated with heparin, whose anticoagulant effect is mediated through the facilitation of thrombin inhibition by 
Figure 5.  The main determinants of each thrombin dynamics parameter in 122 healthy subjects. (A) The 
influence of prothrombin and FX levels on the  PCtot, (B) of prothrombin and FX levels on the  PCmax, (C) FII 
and FX levels on T-AT formation, (D) AT and α2M levels on T-α2M formation and (E) AT and fibrinogen levels 
on the TDC. 3D plots show the overall trend of the data as a color coded mesh, ranging from blue (low values) 
through green and yellow to red (high values).
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 AT25, the balance between T-AT and T-α2M shifts towards the formation of T-AT complexes. On the contrary, 
in subjects with low AT levels or high α2M levels, such as liver cirrhosis patients and young children, the balance 
between T-AT and T-α2M has been shown to shift in favor of T-α2M  complexes21,26.
Figure 6.  Prothrombin conversion and thrombin inactivation in haemophilia A. Thrombin generation and 
thrombin dynamics were determined at 1 pM TF in 60 (male) controls and 8 hemophilia A patients . Average 
thrombin generation curves (A) were calculated for the controls (black) and hemophilia patients (red). The 
average prothrombin conversion curve at 1 pM TF were calculated for the same groups (B). Prothrombin 
conversion was quantified as  PCtot (C) and  PCmax (D), and thrombin inactivation was measured by T-AT (E) 
and T-α2M (F). Reference ranges are depicted as grey boxes, dots show individual values and the lines indicate 
the median ± interquartile range. Statistical significance was tested by Mann–Whitney test and indicated as 
**** < p < 0.0001.
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We have used thrombin dynamics analysis to study the process of prothrombin conversion and thrombin 
dynamics in multiple clinical settings. Thrombin generation shows a deviation in certain patients groups, but the 
deviation cannot be pinpointed to a specific target process in the coagulation cascade. We used thrombin dynam-
ics analysis to provide more information of the mechanism of disease. Additionally, thrombin dynamics can be 
used to perform in silico experimentation, because of the computational model for thrombin inactivation that 
lies at its basis. This allows us to test research hypothesis in silico as illustrated below with several examples. To 
define what is abnormal we defined normal values for thrombin dynamics parameters  PCtot,  PCmax,T-AT, T-α2M, 
and TDC and compared these results to previously acquired thrombin dynamics data. Supplementary Table 2 
shows an overview of previous clinical thrombin dynamics studies and how the respective patient populations 
relate to the newly established normal  ranges14–22.
Liver cirrhosis causes disturbed blood coagulation due to the reduced production of pro- and anticoagulant 
factors, such as prothrombin, FV, FX, and  antithrombin27–29. As a result, cirrhosis patients suffer from both 
bleeding (eg bruising, ruptured esophageal varices) and thrombosis (eg deep venous thrombosis, pulmonary 
embolism)30,31. Nevertheless, routine clinical tests such as the prothrombin time indicate increased bleeding risk, 
whereas thrombin generation correlates better with the hemostatic situation in cirrhosis  patients27. We found 
that prothrombin and antithrombin levels were significantly reduced to respectively 43% and 39% in severe liver 
 cirrhosis21. In contrast, α2Macroglobulin was increased up to twofold resulting in decreased  PCtot, T-AT and 
TDC values in thrombin dynamics analysis. In addition, T-α2M levels are elevated compared to healthy subjects 
and newly established reference values.
Children hardly ever suffer from  thrombosis32 and thrombin generation is reduced in children compared to 
 adults33–35. We recently investigated the mechanism behind this change and found that prothrombin conversion 
 (PCtot and  PCmax) is lower in children compared to  adults20. Additionally, the balance between antithrombin 
and α2M for the inhibition of thrombin shifts more towards α2M. Nevertheless, liver disease in children causes 
striking similarities to the changes in  adults36. However, the impressive reduction of prothrombin conversion 
provides an explanation for the diminished risk of pediatric thrombosis.
Hemophilia A is a genetic disorder that causes low or undetectable levels of the pro-coagulant FVIII and sub-
sequently, patients have a severe risk of bleeding. Thrombin generation, prothrombin conversion and thrombin 
inactivation are reduced in  hemophilia6,37, and has been used in the past to estimate a patients risk of  bleeding38. 
A novel treatment approach in hemophilia is to attack the anticoagulant pathway, in an attempt to bring the 
pro- and anticoagulant process in  balance11. We used the thrombin dynamics method and in silico simulations to 
investigate the effect of antithrombin-targeting in haemophilia A patients on thrombin dynamics and thrombin 
generation (unpublished work). A 50% reduction of antithrombin could increase thrombin generation peak 
height in haemophilia A patients by 80%. However, the variation in effect between patients was large, depending 
on their initial thrombin generation profile, and therefore, pre-therapeutic dose adjustment using the thrombin 
dynamics method might be interesting.
The thrombin generation method and subsequently the quantification of prothrombin conversion and throm-
bin inactivation have some limitations associated with in vitro testing. One limitation is the absence of platelets 
in the measurements in the current work. However, thrombin generation can also be measured in platelet rich 
 plasma39. Furthermore, we have recently published that thrombin dynamics analysis can also be performed in 
platelet rich plasma and that the measurement parameters are sensitive to the platelet  number40. Another limita-
tion is the lack of the vessel wall, which plays a role in in vivo coagulation. In thrombin generation, this can be 
mimicked partially using soluble  thrombomodulin1. Therefore, the results of thrombin generation, prothrombin 
conversion and thrombin inactivation measurements in vitro can be different than in vivo. Nevertheless, throm-
bin generation has been shown to be a useful indicator of bleeding and thrombosis  risk2–8.
In conclusion, we show that prothrombin conversion is mainly influenced by prothrombin, FX and antithrom-
bin levels, whereas thrombin inactivation is dependent on antithrombin and fibrinogen. Our study provides a 
better insight into the relation between coagulation factors and dynamic thrombin activity. The established refer-
ence values of thrombin dynamics will provide guidance values for clinically ‘normal’ and ‘abnormal’ thrombin 
dynamics parameter values. Our approach allows a more detailed insight into the mechanistic background of 
alterations of coagulation in specific patient populations and contributes in the design of therapeutic strategies 
in hemostatic diseases.
Methods
Sample collection. Our study protocols were evaluated by the local medical ethical boards (Medical Ethi-
cal Committee of Maastricht University Medical Center or Erasmus Medical Center Rotterdam). All research 
was performed in accordance with the relevant guidelines and regulations, and all volunteers gave full informed 
consent according to the Helsinki declaration. The study population consisted of 122 healthy adult individuals, 
aged 18–65 years. None of the participants used oral anticoagulant or anti-platelet drugs for at least two weeks, 
had a history of thrombosis or bleeding. Additionally, 8 haemophilia A patients were included. Blood was col-
lected into vacuum tubes (1 volume trisodium citrate 0.105 M to 9 volumes blood) (BD Vacutainer System/
Greiner). Platelet-poor plasma (PPP) was obtained by double centrifugation at 2630 g for 10 min and stored at 
− 80 °C until further use.
Materials. Hepes buffers containing 5 mg/ml or 60 mg/ml bovine serum albumin were used to dilute the 
reagents or substrates, respectively, as described  before13. Bovine serum albumin and unfractionated heparin 
and were purchased at Sigma-Aldrich (Darmstadt, Germany). The chromogenic thrombin substrate, S2238, was 
synthesized in house (Synapse Research Institute, Maastricht, the Netherlands)41. Bovine thrombin and bovine 
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antithrombin were purified according to the protocols of Church et al. and Thaler et al. (Synapse Research Insti-
tute, Maastricht, the Netherlands)42,43.
coagulation factor determinations. All coagulation factor levels except α2-macroglobulin (fibrinogen, 
FII, FV, FX, and antithrombin) were determined on the STA-R Evolution analyzer (Diagnostica Stago, Asnières, 
France). Fibrinogen levels were measured with the Claus assay. Functional α2M levels were determined in house 
as previously described (Synapse Research Institute, Maastricht, the Netherlands)14.
thrombin generation. Calibrated Automated Thrombinography (CAT) was performed as previously 
described. PPP reagent low and PPP reagent, corresponding to 1 and 5 pM tissue factor (Diagnostica Stago, 
Asnières, France) were used according to the manufacturers  description13. The results were analyzed with the 
Thrombinoscope software (Thrombinoscope, Maastricht, the Netherlands). The TG curves were used to per-
form additional computational analysis to extract prothrombin conversion  curves14.
thrombin dynamics. The TG curve is the net result of prothrombin conversion and thrombin inactivation 
and therefore, the prothrombin conversion curve can be calculated from a TG curve.
Thrombin inactivation was predicted by the previously described and validated computational  model14,19,26,44. 
This model consists of a set of ordinary differential equations, which describe the rate of thrombin inactivation 
in time based on the plasma AT, α2M and fibrinogen level and the free thrombin concentration at each point in 
time (Eqs. 1–3).
The amount of thrombin that is free in solution  (Tfree) depends on the amount of thrombin substrate that is 
present, and rate constants for the inactivation of thrombin by antithrombin  (kAT) and α2-macroglobulin  (kαM) 
are dependent on the plasma fibrinogen level, as described in more detail  elsewhere14.
At any moment during the course of the TG process, the TG curve is the net result of prothrombin conversion 
and thrombin inactivation. Therefore, the course of prothrombin conversion (d(P)/dt) can be calculated from the 
TG curve ([T]t) and the inactivation rate of thrombin at a specific thrombin concentration (d(T-inh)/dt) (Eq. 4). 
With the previously described model for thrombin inactivation we can calculate the thrombin inactivation rate 
at each time point during TG (Eq. 5).
Thrombin inactivation can be determined independently of the thrombin generation curve as a parameter 
called the thrombin decay capacity. This is the pseudo-first order decay constant for thrombin that combines 
the overall effect of thrombin inactivation by AT and α2M. In the thrombin dynamics method, the prothrombin 
conversion curve is quantified by its area-under-the-curve, which is the total amount of prothrombin converted 
 (PCtot) throughout the TG experiment, and the peak height of the prothrombin conversion curve, which is the 
maximum rate of prothrombin conversion  (PCmax).
Statistical analysis. Statistical analysis was performed using Graphpad Prism (version 8, San Diego, USA). 
Reference ranges were determined as the 2.5th and 97.5th percentile values of the healthy subjects dataset vari-
ables. Data was presented as the median ± interquartile range. Statistical significance was determined by ANOVA 
analysis with Bonferroni correction or the Mann–Whitney test, dependent on the number of groups that needed 
to be analyzed. Dose–response effects were investigated using linear correlation. Correlations were calculated 
as the Pearson correlation coefficient in the healthy subject sample data. A p-value below 0.05 was considered 
statically significant.
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